Sanofi-Aventis (France) Extends $18.5 Billion Genzyme Corporation Offer to January 21
Wall Street Journal -- French drugs giant Sanofi-Aventis said Monday it has extended its $18.5 billion offer for Genzyme for more than a month without changing the terms, and that only 0.9% of shares had been tendered so far by the target's shareholders. The move was widely expected but will leave shareholders puzzled, as the French group gave few details of its plans or thinking.